ALN-SNCA Investigational alpha-synuclein gene-silencing therapy licensed to Regeneron, undergoing Phase 1 development for Parkinson’s disease within the partnered neurological pipeline.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-SNCA.
Add it to your Products I use list and share why you use it.